Insulin Therapy for Diabetes Management

Initial Insulin Regimen

The American Diabetes Association recommends starting with Mixtard 30/70 administered twice daily, with 2/3 of the total daily dose given before breakfast and 1/3 before dinner 1, 2
The initial total daily dose of Mixtard can be 10 units per day or 0.1-0.2 units/kg body weight, with titration by increasing the dose by 2 units every 3 days to reach the target fasting plasma glucose without hypoglycemia 1
For patients experiencing hypoglycemia without a clear cause, the corresponding dose should be reduced by 10-20% 1, 2

If twice-daily Mixtard fails to achieve glycemic goals, the American Diabetes Association suggests adding prandial Regular insulin or Actrapid before meals, starting with 4 units before the largest meal or 10% of the basal insulin dose 1, 2, 3
When adding prandial insulin, consider reducing the basal dose by 4 units per day or 10% if the A1C is less than 8% 3, 1
The prandial insulin dose can be titrated by increasing it by 1-2 units or 10-15% twice weekly based on postprandial glucose levels 4, 1

The American Diabetes Association recommends using fasting plasma glucose to titrate the basal component and postprandial glucose to titrate the prandial Regular insulin/Actrapid doses 4, 1
The target postprandial glucose level is less than 180 mg/dL (10 mmol/L) at 1-2 hours after meals 5

Regular insulin and Actrapid have a similar profile, with an onset of action in 30 minutes, peak at 2-3 hours, and duration of 6-8 hours 6
The timing of administration is crucial, with Regular insulin/Actrapid given 30 minutes before meals and Mixtard given immediately before breakfast and dinner 6, 1, 2

Hypoglycemia risk is increased with Regular insulin due to its longer duration of action, and monitoring is essential to prevent hypoglycemia, especially overnight 6
Dosing errors, such as using correction doses more frequently than every 4-6 hours, can lead to insulin stacking and hypoglycemia 7
Overbasalization can occur if the basal dose exceeds 0.5 units/kg/day, and signs include elevated bedtime-to-morning glucose differential or frequent hypoglycemia 4, 1

The American College of Endocrinology and the American Diabetes Association acknowledge that regular human insulin can be directly substituted with rapid-acting insulin analogs, such as insulin lispro, insulin aspart, or insulin glulisine, which provide superior postprandial glucose control with lower hypoglycemia risk and greater dosing flexibility, as recommended by the American Association of Clinical Endocrinologists 8, 9

Insulin lispro, insulin aspart, and insulin glulisine are all FDA-approved rapid-acting analogs that can replace regular human insulin for prandial coverage, according to the American Diabetes Association 9

Switching from Actrapid to rapid-acting analogs provides a lower risk of hypoglycemia, particularly nocturnal and late postprandial hypoglycemia, because the shorter duration prevents insulin stacking, as stated by the American College of Endocrinology 8
Comparable or better HbA1c reduction can be achieved with rapid-acting analogs, especially when combined with basal insulin analogs rather than NPH, as recommended by the American Association of Clinical Endocrinologists 8

Any insulin substitution must be done under medical supervision with informed patient consent and increased glucose monitoring during the transition, as advised by the American Diabetes Association 9
Do not substitute long-acting or intermediate-acting insulins for Actrapid—only short-acting or rapid-acting insulins are appropriate prandial replacements, according to the American College of Endocrinology 9

Faster-acting insulin aspart and insulin lispro-aabc are ultra-rapid formulations with enhanced absorption that provide additional postprandial glucose reduction compared to standard rapid-acting analogs, as stated by the American Association of Clinical Endocrinologists 8